Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome

• Status: Unknown status
• Trial end date: 2017-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of 5mg maintenance dose (MD) of prasugrel in patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) with BiomatrixTM stent.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chonnam National University Hospital
• Treatments: Clopidogrel; Prasugrel Hydrochloride

Criteria

Inclusion Criteria:

• Patients who can undergo percutaneous coronary intervention with Biomatrix stent with no history of TIA or stroke,

• 75 years old or younger,

• body weight of 60 kg or more and diagnosed with acute coronary syndrome

Exclusion Criteria:

• Patients with history of TIA or stroke,

• 75 years old or older,

• body weight of 60 kg or under,

• hypersensitivity to or contraindicated for heparin, aspirin, clopidogrel, prasugrel or contrast media